Candida Colonization and Respiratory Infections in Critically Ill Patients

Patients in intensive care units frequently exhibit Candida species in their respiratory tracts without overt invasive disease. Colonisation, which may progress to ventilator-associated complications, is observed in up to a quarter of mechanically ventilated individuals. The interplay between Candida and bacterial pathogens in the lower respiratory tract remains controversial: while some evidence suggests that fungal presence reflects a dysbiotic milieu driven by antibiotic pressure, immune dysregulation and epithelial barrier disruption, others propose a contributory role in inflammatory lung injury. Recent advances have refined diagnostic approaches, incorporating molecular detection and biomarker assays such as (1,3)-β-D-glucan measurements in tracheal aspirates and bronchoalveolar lavage fluid. Despite routine use of antifungal prophylaxis or nebulised amphotericin protocols within selective digestive decontamination regimens, data supporting improved clinical outcomes are limited, and indiscriminate treatment may prolong mechanical ventilation. Current research emphasises species-level identification—particularly the emergence of non-albicans Candida and multidrug-resistant C. auris—and advocates for stewardship strategies that balance eradication of colonisation against the risks of toxicity and resistance. Understanding the global burden of Candida in respiratory secretions underpins targeted surveillance, informs antifungal selection and guides interventional trials aimed at optimising care in the critically ill.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Candida Colonization and Respiratory Infections in Critically Ill Patients publication trend

The graph below shows the total number of articles in candida colonization and respiratory infections in critically ill patients across all publications each year (not limited to Nature Index journals).

Technical terms

Colonisation: Presence of microorganisms on mucosal surfaces without tissue invasion or host response sufficient to cause disease.

Ventilator-associated pneumonia (VAP): Infection of the lower respiratory tract developing after 48 hours of endotracheal intubation and mechanical ventilation.

Non-albicans Candida (NAC): Species of Candida other than C. albicans, often exhibiting distinct virulence factors and drug resistance profiles.

(1,3)-β-D-glucan: A polysaccharide component of the fungal cell wall measured in biological fluids as a biomarker for invasive fungal infection.

References

1. Yeast species in the respiratory samples of COVID-19 patients; molecular tracking of Candida auris. Frontiers in Cellular and Infection Microbiology (2024).
2. Isolation of Candida Species Is Associated with Comorbidities, Prolonged Mechanical Ventilation, and Treatment Outcomes in Surgical ICU Patients, a Cross-Sectional Study. Journal of Fungi (2024).
3. Retrospective analysis on distribution and antifungal susceptibility profile of Candida in clinical samples: a study from Southern India. Frontiers in Public Health (2023).
4. Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study. Critical Care (2013).
5. The significance of Candida in the human respiratory tract: our evolving understanding. Pathogens and Disease (2017).
6. Measuring (1,3)-β-D-glucan in tracheal aspirate, bronchoalveolar lavage fluid, and serum for detection of suspected Candida pneumonia in immunocompromised and critically ill patients: a prospective observational study. BMC Infectious Diseases (2017).